 | Up a level |
Dellapasqua, Silvia; Gray, Kathryn P.; Munzone, Elisabetta; Rubino, Daniela; Gianni, Lorenzo; Johansson, Harriet; Viale, Giuseppe; Ribi, Karin; Bernhard, Jürg; Kammler, Roswitha; Maibach, Rudolf; Rabaglio, Manuela; Ruepp, Barbara; Di Leo, Angelo; Coates, Alan S.; Gelber, Richard D.; Regan, Meredith M.; Goldhirsch, Aron; Colleoni, Marco (2019). Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. Journal of clinical oncology, 37(5), pp. 386-395. American Society of Clinical Oncology 10.1200/JCO.18.00296
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia; Regan, Meredith M; Viale, Giuseppe; Aristarco, Valentina; Macis, Debora; Puccio, Antonella; Roux, Susanne; Maibach, Rudolf; Colleoni, Marco; Rabaglio, Manuela; Price, Karen N; Coates, Alan S; Gelber, Richard D; Goldhirsch, Aron; Kammler, Roswitha; Bonanni, Bernardo; Walley, Barbara A (2016). Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast cancer research, 18(1), p. 110. BioMed Central Ltd. 10.1186/s13058-016-0771-8
Decensi, Andrea; Sun, Zhuoxin; Guerrieri-Gonzaga, Aliana; Thürlimann, Beat; McIntosh, Christina; Tondini, Carlo; Monnier, Alain; Campone, Mario; Debled, Marc; Schönenberger, Astrid; Zaman, Khalil; Johansson, Harriet; Price, Karen N; Gelber, Richard D.; Goldhirsch, Aron; Coates, Alan S.; Aebi, Stefan (2014). Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast cancer research and treatment, 144(2), pp. 321-329. Springer 10.1007/s10549-014-2849-2
